The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.

Affinity's COVID-19 antibodies ready for manufacture for clinical trials - BSA bureau


SOURCE: Biospectrumasia.com

Click here to READ THE FULL STORY.

Menu